Clinical Trial Update: High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating high-dose icotinib beyond progression in patients with EGFR-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN